Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ): Food and Drug Admi...
The European Commission approved the expanded use of Blueprint Medicines' (NASDAQ:BPMC) Ayvakyt (avapritinib) as a monotherapy for adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least o...
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis PR Newswire -- AYVAKYT is the first approved therapy in the European Union designed to selectively target the KIT D816...
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022 -- Blueprint Medicines to host investor conference call and webcast on Friday, April 8, 2022 -- PR Newswire CAMBRIDGE, Mass. , March 8, 2022 /PRNewswire/ -- Blueprint...
Blueprint Medicines (NASDAQ:BPMC) and Proteovant Therapeutics will collaborate on protein degrader therapies and advance up to two candidates into development. The collaboration will utilize Proteovant's artificial intelligence-assisted targeted protein degradation platform and Blueprint Medi...
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies -- Collaboration will leverage Proteovant's Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines' small...
Shares of Blueprint Medicines (BPMC -5.1%) are down in morning trading after at least two Street firms weighed in on the company's Q4 2021 results released Wednesday. Those results also included a lower-than-expected revenue guidance for 2022. While maintaining a buy rating, H.C. Wainwri...
Blueprint Medicines Corporation (BPMC) Q4 2021 Earnings Conference Call February 16, 2022 8:30 AM ET Company Participants Kristin Hodous – Senior Manager-Investor Relations Jeff Albers – Chief Executive Officer Kate Haviland – Chief Operating Officer Christy Rossi –...
Blueprint Medicines (BPMC -9.1%) is trading sharply lower in the morning hours on Wednesday after the company initiated a lower-than-expected revenue guidance for 2022. Announcing its Q4 2021 results, Blueprint (NASDAQ:BPMC) reported $107M in quarterly revenue, including $20.0M net product re...
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and w...
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics PR Newswire -- Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members ...
2024-04-10 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...